TNXP Tonix Pharmaceuticals Holding Corp
69,775
$0.182
$0.0045
(2.54%)
| Watchers | 69,775 |
| 52-Wk Low | $0.1202 |
| 52-Wk High | $2.13 |
| Market Cap | $15M |
| Volume | 361,104.00 |
| 52-Wk High | $2.13 |
| 52-Wk Low | $0.1202 |
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsGlobe Newswire • about 1 month ago
Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for...
Share to Feed
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 967,000...
CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ( Tonix or the Company ), a biopharmaceutical company, today announced it has entered into a...
TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi syndrome is the most common genetic...
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder...
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by positive results from two Phase 3 studies New Drug Application (NDA...
Zembrace SymTouch and Tosymra will be marketed by Tonix Medicines, Tonix's wholly-owned commercial subsidiary Commercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya for...
Tonix recently reported results from second positive Phase 3 trial of Tonmya for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second...
Phase 3 RESILIENT study of Tonmya met its primary endpoint of daily pain reduction (p=0.00005) and achieved statistically significant improvement on all six key pre-specified secondary endpoints with...
New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT
Show...